10x Genomics Inc. (TXG)
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10x Genomics Q1 Earnings Call Highlights
10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company's history.
10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.36 per share a year ago.
10x Genomics (TXG) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics Stock Up on Atera Launch, Spatial Biology Scale Enhanced
TXG stock jumps after unveiling Atera, a next-gen spatial biology platform aiming to scale single-cell analysis and deepen its role in drug discovery and research.
10x Genomics: Undervalued Amid Consumables-Led Transition
10x Genomics is undervalued, with a BUY rating and 18% upside to a $20.47 target, driven by robust consumables growth. Consumables, comprising 83% of revenue, continue double-digit growth, offsetting post-COVID instrument sales normalization and supporting recurring revenue expansion. TXG maintains a dominant 34% market share in single-cell biology, reinforced by increasing academic mindshare and strategic partnerships to drive future penetration.
10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript
10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript
